PFIZER INC

Pfizer’s latest quarterly earnings reveal modest growth from licensing deals and partnership milestone payments, positioning the pharma firm for future cash‑flow recovery and long‑term upside.

Pfizer’s Q3 earnings beat, driven by vaccine, oncology and immunology gains, showcases robust growth and a strong cash position poised for future expansion.

Pfizer adds veteran Geno Germano to its board—will it spark a breakthrough pipeline or just shore up governance? Discover the strategic impact.

Pfizer strengthens governance by adding seasoned leader Geno Germano to its board, positioning the firm for accelerated pipeline progress and stable market value.